Menu Search
Equities

Castle Biosciences Inc

CSTL:NMQ

Castle Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)33.29
  • Today's Change-0.02 / -0.06%
  • Shares traded396.27k
  • 1 Year change+85.36%
  • Beta0.9471
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Castle Biosciences Inc grew revenues 60.38% from 137.04m to 219.79m while net income improved from a loss of 67.14m to a smaller loss of 57.47m.
Gross margin81.90%
Net profit margin1.95%
Operating margin-0.33%
Return on assets1.28%
Return on equity1.47%
Return on investment1.40%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Castle Biosciences Inc fell by 24.11m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 5.63m for operations while cash used for investing totalled 16.18m.
Cash flow per share0.6934
Price/Cash flow per share47.74
Book value per share15.77
Tangible book value per share11.81
More ▼

Balance sheet in USDView more

Castle Biosciences Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio7.78
Quick ratio7.64
Total debt/total equity0.0234
Total debt/total capital0.0228
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 16.80%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago		107.04
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.